Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
1. Dexcom's Q4 revenue rose 8% year-over-year to $1.114 billion, beating estimates. 2. U.S. revenue increased by 4%, while international revenue grew by 17%. 3. Dexcom reaffirmed its FY25 guidance, expecting $4.60 billion in revenue. 4. Settlement with Abbott ends patent disputes, allowing focus on growth. 5. Analysts foresee strong long-term growth despite short-term execution challenges.